Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose-escalation Study of GSK2330672 in Japanese Healthy Male Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02801981
Recruitment Status : Completed
First Posted : June 16, 2016
Last Update Posted : November 9, 2016
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
This study will be the first to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics following single dose of 10 milligrams (mg) to 180 mg of GSK2330672 in Japanese healthy subjects. This is a double-blind, randomized, placebo-controlled, dose-escalating and incomplete block crossover study to be conducted in 16 Japanese healthy subjects. Study will be conducted in four periods; subjects will receive either placebo or GSK2330672 (10 mg, 30 mg, 90 mg or 180 mg based on randomization) in each treatment period. Each period will be separated by washout period (at least 6 days from dosing). Total duration of study for each subject will be approximately 5 weeks from the first dosing to follow up visit.

Condition or disease Intervention/treatment Phase
Cholestasis Drug: GSK2230672 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo Controlled, Dose Escalating Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Parameters of Single Doses of GSK2330672 in Japanese Healthy Male Volunteers
Study Start Date : June 2016
Actual Primary Completion Date : August 2016
Actual Study Completion Date : August 2016

Arm Intervention/treatment
Experimental: Sequence 1: GSK2230672 10mg, 30mg, 90mg, and Placebo
Subjects will receive GSK2230672 10 mg in period 1, GSK2230672 30 mg in Period 2, GSK2230672 90 mg in Period 3 and placebo in period 4.
Drug: GSK2230672
It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.

Drug: Placebo
It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672

Experimental: Sequence 2:GSK2230672 10mg, 30mg, Placebo, and GSK2230672 90mg
Subjects will receive GSK2230672 10 mg in period 1, GSK2230672 30 mg in Period 2, placebo in period 3, and GSK2230672 90 mg in period 4.
Drug: GSK2230672
It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.

Drug: Placebo
It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672

Experimental: Sequence 3:GSK2230672 10mg, Placebo, GSK2230672 90mg and 180mg
Subjects will receive GSK2230672 10 mg in period 1, placebo in Period 2, GSK2230672 90 mg in Period 3 and GSK2230672 180 mg in period 4.
Drug: GSK2230672
It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.

Drug: Placebo
It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672

Experimental: Sequence 4: Placebo, GSK2230672 30mg, 90mg and 180mg
Subjects will receive placebo in period 1, GSK2230672 30 mg in Period 2, GSK2230672 90 mg in Period 3 and GSK2230672 180 mg in period 4.
Drug: GSK2230672
It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.

Drug: Placebo
It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672




Primary Outcome Measures :
  1. Number of Subjects with Adverse events (AE) [ Time Frame: Maximum of 5 weeks ]
  2. Safety as assessed by blood pressure [ Time Frame: Maximum of 5 weeks ]
    Systolic and diastolic blood pressure will be measured on Day -1, post dose 2 hours (hrs), 12.5 hrs, 24.5 hrs and at 48 hrs in each period and at follow-up.

  3. Safety as assessed by heart rate [ Time Frame: Maximum of 5 weeks ]
    Heart rate will be measured on Day -1, post dose 2 hrs, 12.5 hrs, 24.5 hrs and at 48 hrs in each period and at follow-up.

  4. Safety as assessed by body temperature [ Time Frame: Maximum of 5 weeks ]
    Body temperature will be measured on Day -1, post dose 2 hrs, 12.5 hrs, 24.5 hrs and at 48 hrs in each period and at follow-up.

  5. Safety as assessed by clinical chemistry parameters [ Time Frame: Maximum of 5 weeks ]
    Blood sample will be collected on Day -1, at 48 hrs in each period and at follow-up

  6. Safety as assessed by haematology [ Time Frame: Maximum of 5 weeks ]
    Blood sample will be collected on Day -1, at 48 hrs in each period and at follow-up

  7. Safety as assessed by urinalysis [ Time Frame: Maximum of 5 weeks ]
    Sample will be collected on Day -1, at 48 hrs in each period and at follow-up

  8. Safety as assessed by fecal occult blood [ Time Frame: Maximum of 5 weeks ]
    Fecal occult blood testing will be conducted on Screening (2 samples during Screening period) and each dosing period (anytime from dosing to next dose).

  9. Safety as assessed by Electrocardiogram (ECG) [ Time Frame: Maximum of 5 weeks ]
    Electrocardiogram will be measured on Day -1, post dose 2 hrs, 12.5 hrs, 24.5 hrs and at 48 hrs in each period and at follow-up.


Secondary Outcome Measures :
  1. Plasma concentration of GSK2330672 [ Time Frame: Blood samples will be collected predose and post dose at 0.5 hrs, 2 hr, 3.5 hr, 5 hr on Day 1 of each period ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 64 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Japanese male aged between 20 and 64 years of age inclusive, at the time of signing the informed consent
  • Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and 12-lead ECG. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator (in consultation with the Medical Monitor if required) agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Regular bowel movement >=1 per two days.
  • Body weight >= 50 kilogram and body mass index (BMI) is more than or equal to 18.5 kilogram / square meter (kg/m^2) and less than 25.0 kg/m^2
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.

Exclusion Criteria:

  • Alanine transaminase (ALT) and/or bilirubin >1.5x Upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome)
  • QT interval corrected for heart rate according to Fridericia's formula (QTcF) > 450 millisecond (msec)
  • Current or chronic history of inflammatory bowel disease, chronic diarrhea, Crohn's disease or malabsorption syndromes.
  • Current or chronic history of cholelithiasis, inflammatory gall bladder disease, cholestatic liver injury, and cholecystecomy.
  • Fecal occult blood test positive at screening.
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (includes St. John's Wort) within 14 days or 5 half-lives, whichever is longer, prior to the first dose of study medication.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks. One drink is equivalent to 12 grams (g) of alcohol: 350 millilitre (mL) of beer, 150 mL of wine or 45 mL of 80 proof distilled spirits.
  • History or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation
  • A positive pre-study syphilis, Hepatitis B surface antigen, Hepatitis C antibody, Human Immunodeficiency Virus (HIV) antigen antibody or Human T-cell Lymphotropic Virus-1 (HTLV-1) antibody result of screening
  • A positive pre-study urine drug screen.
  • History of donation of blood or blood products >= 400 mL within 3 months or >= 200 mL within 1 month prior to screening.
  • The subject has participated in a clinical trial and has received an investigational product within four months or 5 half-lives (whichever is longer) prior to the dosing day in the current study
  • Exposure to more than four new chemical entities within 12 months prior to the dosing day.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02801981


Locations
Layout table for location information
Japan
GSK Investigational Site
Tokyo, Japan, 192-0071
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT02801981    
Other Study ID Numbers: 205808
First Posted: June 16, 2016    Key Record Dates
Last Update Posted: November 9, 2016
Last Verified: November 2016
Keywords provided by GlaxoSmithKline:
tolerability
healthy volunteers
Cholestasis
safety
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholestasis
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases